Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 240

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 240
---
 Shares that would exceed 9.99% of our then outstanding share capital following such exercise. The principal business 
 address of Brio Capital Management LLC is 100 Merrick Rd., Suite 401W, Rockville Centre, NY 11570.                                            |

| (3) | Based primarily on the Schedule 13G/A filed by Cavalry Fund                                                                               
 I LP on September 30, 2024, and our information and belief. Consists of (i) warrants to purchase an aggregate of 1,579,290,000 Ordinary   
 Shares (in the form of Depositary Shares) beneficially owned by Cavalry Investment Fund I, LP and (ii) warrants to purchase an aggregate  
 of 90,560,000 Ordinary Shares (in the form of Depositary Shares) beneficially owned by Cavalry Investment Fund LP. Cavalry Fund I         
 Management LLC, the investment manager of Cavalry Fund I LP and Cavalry Investment Fund LP, has voting and investment power               
 over these securities. Thomas Walsh is the managing member of Cavalry Fund I Management LLC, which is the general partner of Cavalry Fund 
 I LP and Cavalry Investment Fund LP. Thomas Walsh disclaims beneficial ownership over these securities. The percentage in this            
 table reflects that the reporting persons may not exercise the warrants to the extent such exercise would cause the reporting persons     
 to beneficially own a number of Ordinary Shares that would exceed 9.99% of our then outstanding share capital following such exercise.    
 The principal business address of the reporting person is 82 E. Allendale Rd., Ste 5B, Saddle River,                                      
 NJ 07458.                                                                                                                                 |

| (4) | Shares owed by Ms. Merchant are Ordinary Shares subject to outstanding stock options which are exercisable 
 at December 31, 2024 or will become exercisable within 60 days after such date.                            |

| (5) | Shares owed by Dr. Parker are Ordinary Shares subject to outstanding stock options which are exercisable 
 at December 31, 2024 or will become exercisable within 60 days after such date.                          |

| (6) | Shares owned by Mr. Stamp are Ordinary Shares subject to outstanding stock options which are exercisable 
 at December 31, 2024 or will become exercisable within 60 days after such date.                          |

| (7) | Shares owned by Dr. Turton include 7,200,000 Ordinary Shares subject to outstanding stock options which 
 are exercisable at